

#### CMED 305

# **Cohort Studies**

Kholood Altassan, MBBS, PhD Assistant Professor - Community Medicine Unit, Family & Community Medicine Department Learning Objectives: By end of this session students will be able to:

1. Describe the types of cohort studies

2. Describe the design of cohort studies

3. Identify steps for conducting cohort studies

4. Identify issues in the design of cohort studies

5. Describe the strengths and weaknesses of cohort studies





A cohort study is an analytical observational study in which a group of people with a common experience <u>(the</u> <u>cohort)</u> is <u>followed over time</u> to find how many reach a specified outcome of interest (disease, condition, event, death, or a change in health status or behavior).

- Term <u>"cohort"</u> is defined as a group of people, usually 100 or more in size, who share a common characteristic or experience within a defined time period (e.g., age, occupation, exposure to a drug or vaccine, pregnancy, and insured persons).
- The <u>comparison group</u> may be the general population from which the cohort is drawn, or it may be another cohort of persons thought to have had little or no exposure to the substance in question, but otherwise similar.

## When to Conduct a Cohort Study

- When there is **good evidence of an association** between exposure and disease based on previous studies
- When <u>exposure is rare</u>, but the incidence of disease high among exposed, e.g. special exposure groups like those in industries, or exposure to X-rays
- When <u>attrition</u> (loss during follow up) of study population <u>can be</u> <u>minimized</u>, e.g. follow-up is easy, cohort is stable, cooperative and easily accessible
- When feasible because time and resources are available





Two types of cohort studies have been distinguished based on <u>the timing</u> at which the investigation is initiated; <u>before</u> or <u>after the</u> <u>outcome</u> has occurred.



## Steps in conducting a cohort study

1- Define a **source population** 

2- Select Study Populations (cohort & comparison): two methods: based on exposure status OR based on factor other than exposure e.g. geographic location

3- Measure the **exposure** 

4- Follow up at intervals to get accurate outcome data

5- Analyze data

#### **Measuring Exposure**

Levels of exposure are measured for each individual at:

- 1. baseline at the beginning of the study and
- 2. assessed at intervals during the period of follow-up.
- A particular problem occurring in cohort studies is whether <u>individuals in the control</u> <u>group are truly unexposed.</u>
- Similarly, those in the <u>exposed group may</u> <u>change their</u> behaviour in relation to the exposure such as diet, smoking or alcohol consumption.
- **Sources for Exposure data:** medical or employment records, standardized questionnaires, interviews and by physical examination and biomarkers.

#### Measuring Outcome

**Sources for outcome data:** routine surveillance of cancer registry data, death certificates, medical records or directly from the participant.

 Method used to ascertain outcome must be <u>identical for both exposed and</u> <u>unexposed groups.</u> The data are analyzed in terms of:

1. Incidence rates of outcome among exposed and non-exposed

2. Estimation of risk:

- Relative Risk (also knows Risk Ratio) (RR)
- Attributable Risk (AR) or Rate Ratio

# What is the difference between prevalence and incidence?

#### Prevalence

- Outcome has already developed and been ascertained
- Prevalence rate uses unit of person (or ppl per 1000)
- Cross-sectional studies

## Incidence

- Newly developed during the course of study based on the time till outcome develops
- Incidence rate uses unit of per person-time (e.g. person-years or personmonths)
- Cohort studies



## **Incidence Rate and Measures of Risk**

## Vaping and Pulmonary illness

Cohort study of vaping and pulmonary illness followed for 1 year.

**Exposure:** vaping **Outcome:** pulmonary illness

	Pulmonary Illness	No Pulmonary Illness	Total
vaping	42	27,000	27,042
No vaping	7	63,000	63,007
Total	49	90,000	90,049

	Pulmonary Illness	No Pulmonary Illness	Total
vaping	42	27,000	27,042
No vaping	7	63,000	63,007
Total	49	90,000	90,049

IR	RR	AR
IR among exposed	= 1.5/0.1	$= \frac{1.5 - 0.1}{0.4} \times 100$
= 42/27,042 = 1.5/1000 person-year	= 15	0.1 = 93%

IR among unexposed

- = 7/63,007
- = 0.1/1000 person-year

## **Translation**

What does a relative risk of 15 mean? The risk of developing pulmonary illness is 15 times higher among those who vaped compared to those who did not.

What does an attributable risk of 93% mean? 93% of pulmonary illness among subjects may be attributed to vaping



#### Loss to Follow Up

• Cohort members may die, migrate, change jobs or withdraw from the study.

 In addition, losses to follow-up may be related to the exposure, outcome or both which can lead to biases.

### **Differential Misclassification of Subjects**

 A major source of potential bias in cohort studies arises from the degree of accuracy with which subjects have been classified with respect to their exposure or disease status.

 Differential misclassification can lead to an over or underestimate of the effect between exposure and outcome

#### **Selection Bias**

Selection bias is more common in case-control studies.

- However, it can happen in <u>cohort studies</u> if:
  - 1. Loss of follow-up is different among exposed and unexposed.
  - 2. Outcome ascertainment differs between exposed and unexposed.
  - 3. Healthy worker effect

## Confounding

- 1. Associated with both exposure
- 2. Causing the outcome
- 3. Should not lie in the causal pathway





#### Strengths

- <u>Multiple outcomes</u> can be measured for any <u>one exposure</u>.
- Exposure is measured before the onset of disease (in prospective cohort studies) so temporality is confirmed.
- Good for measuring <u>rare exposures.</u>
- Demonstrate causality.
- Can measure incidence rate.

#### Weaknesses

- Costly and time consuming.
- Prone to selection bias due to loss to follow-up and healthy worker effect.
- Prone to confounding.
- Participants may move between exposure categories.
- Observer bias
- Being in the study may alter participant's behavior.
- Poor choice for the study of a rare disease (rare outcome).
- Classification of individuals (exposure or outcome status) can be affected by changes in diagnostic procedures.

## Thank you!

Office Hours (by appointment via email): k.k.altassan@gmail.com

nmalamro@ksu.edu.sa

#### References:

- Celentano, David D., and Scd Mhs. Gordis Epidemiology. Elsevier, 2018.
- Hulley, Stephen B., ed. Designing clinical research. Lippincott Williams & Wilkins, 2007.
- Haynes, R. Brian. Clinical epidemiology: how to do clinical practice research. Lippincott williams & wilkins, 2012.
- Carlson, Melissa DA, and R. Sean Morrison. "Study design, precision, and validity in observational studies." Journal of palliative medicine 12.1 (2009): 77-82.
- The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Study Design. NA. Accessed September 13, 2019: https://www.cebm.net/2014/04/study-designs/
- Alexander, Lorraine K., Brettania Lopes, Kristen Ricchetti-Masterson, and Karin B. Yeatts. "ERIC notebook." 2014. Accessed September 27, 2019: https://sph.unc.edu/files/2015/07/nciph\_ERIC6.pdf
- Coggon, David, David Barker, and Geoffrey Rose. Epidemiology for the Uninitiated. John Wiley & Sons, 2009.
- Hennekens, Charles H., and J. E. Buring. "Cohort studies." Epidemiology in medicine (1987).